• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Merck pays $50 million for early-stage Epstein-Barr vaccine

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 08, 2023 at 09:52: PM
via Merck & Co. has added another experimental vaccine to its pipeline, paying $50 million to Opko Health for a preclinical candidate aimed at the Epstein-Barr virus, which causes mononucleosis and is linked to multiple sclerosis and some types of cancer.

article source
 




Top Bottom
Back
Quote